



SIRT1 Direct Fluorescent Screening Assay Kit

Catalog Number KA1366

96 assays

Version: 04

Intended for research use only

www.abnova.com

Table of Contents

Introduction	3
Background	3
Principle of the Assay	4
General Information	5
Materials Supplied	5
Storage Instruction	5
Materials Required but Not Supplied	5
Precautions for Use	5
Assay Protocol	6
Reagent Preparation	6
Assay Procedure	6
Data Analysis.....	8
Calculation of Results.....	8
Performance Characteristics	8
Resources	10
Troubleshooting.....	10
References	10
Plate Layout	12

Introduction

Background

Nucleosomes, which fold chromosomal DNA, contain two molecules each of the core histones H2A, H2B, H3, and H4. Almost two turns of DNA are wrapped around this octameric core, which represses transcription.¹ The histone amino termini extend from the core, where they can be post-translationally modified by acetylation, phosphorylation, ubiquitination, and methylation, affecting their charge and function. Acetylation of the ϵ -amino groups of specific histone lysines is catalyzed by histone acetyltransferases (HATs) and correlates with an open chromatin structure and gene activation. Histone deacetylases (HDACs) catalyze the hydrolytic removal of these acetyl groups from histone lysine residues and correlates with chromatin condensation and transcriptional repression.^{2,3}


The sirtuins represent a distinct class of trichostatin A-insensitive lysyl-deacetylases (class III HDACs) and have been shown to catalyze a reaction that couples lysine deacetylation to the formation of nicotinamide and O-acetyl-ADP-ribose from NAD⁺ and the abstracted acetyl group.⁴⁻⁶ There are seven human sirtuins which have been designated SIRT1-SIRT7.⁷ SIRT1, which is located in the nucleus, is the human sirtuin with the greatest homology to yeast Silent information regulator 2 (Sir2) and has been shown to regulate the activity of the p53 tumor suppressor and inhibit apoptosis.⁸⁻¹⁰ These results have significant implications regarding an important role of SIRT1 in modulating the sensitivity of cells in p53-dependent apoptotic response and the possible effect in cancer therapy. Since the growth suppressive function of p53 is strongly enhanced by DNA damaging reagents, it is expected that inhibitors of SIRT1 may be effective anticancer drugs.^{11,12}

Recent screens for modulators of SIRT1 activity yielded a number of small molecule activators. Several of these activating compounds extended yeast, *D. melanogaster*, and *C. elegans* lifespans in a way that mimicked caloric restriction.^{13,14} Resveratrol, the most potent of these compounds, activated SIRT1 in human cells and enhanced the survival rate of cells stressed by irradiation.¹³ However, this activation of SIRT1 is under the subject of debate. It was determined that the in vitro activation of SIRT1 and Sir2 by resveratrol was a substrate-specific event (i.e., the binding of resveratrol to SIRT1 promoted a conformational change that better accommodated the attached coumarin group in the peptide substrate.)^{15,16} Additional research needs to be done to further elucidate the mechanism behind SIRT1 activation, as well as to establish the role of SIRT1 activation in aging, cancer, and neurodegenerative disease.^{17,18}

Principle of the Assay

SIRT1 Direct Fluorescent Screening Assay Kit provides a convenient fluorescence-based method for screening SIRT1 inhibitors or activators. The procedure requires only two easy steps, both performed in the same microplate (Figure 1). In the first step, the substrate, which comprises the p53 sequence Arg-His-Lys-Lys(ϵ -acetyl)-AMC, is incubated with human recombinant SIRT1 along with its cosubstrate NAD^+ . Deacetylation sensitizes the substrate such that treatment with the developer in the second step releases a fluorescent product. The fluorophore can be easily analyzed using an excitation wavelength of 350-360 nm and an emission wavelength of 450-465 nm.

Figure 1.



General Information

Materials Supplied

List of component

Component	Amount
SIRT1 Direct Assay Buffer (10X)	1 vial
SIRT1 (human recombinant)	2 vials
SIRT1 Direct Peptide	2 vials
SIRT1 Direct NAD ⁺	1 vial
SIRT1 Direct Nicotinamide	1 vial
SIRT1 Direct Developer	1 vial
SIRT1 Direct Fluorophore	1 vial
Half Volume 96-Well Plate (white)	1 plate
96-Well Cover Sheet	1 cover

Storage Instruction

This kit will perform as specified if stored at -80°C and used before the expiration date indicated on the outside of the box.

Materials Required but Not Supplied

- ✓ A fluorometer with the capacity to measure fluorescence using excitation wavelength of 350-360 and emission wavelength of 450-465 nm.
- ✓ Adjustable pipettes and a repeat pipettor.
- ✓ A source of pure water. Glass distilled water or HPLC-grade water is acceptable.

Precautions for Use

Warning: This product is for laboratory research use only: not for administration to humans. Not for human or veterinary diagnostic or therapeutic use.

- ✓ Pipetting Hints
 - It is recommended that an adjustable pipette be used to deliver reagents to the wells.
 - Before pipetting each reagent, equilibrate the pipette tip in that reagent (i.e., slowly fill the tip and gently expel the contents, repeat several times).
 - Do not expose the pipette tip to the reagent(s) already in the well.

Assay Protocol

Reagent Preparation

- ✓ SIRT1 Direct Assay Buffer (10X) - Dilute 3 mL of Assay Buffer concentrate with 27 mL of HPLC-grade water. This final Buffer (50 mM Tris-HCl, pH 8.0, containing 137 mM NaCl, 2.7 mM KCl, and 1 mM MgCl₂) should be used in the assay and for diluting reagents. When stored at 4°C, this diluted buffer is stable for at least six months.
- ✓ SIRT1 (human recombinant) - Each vial contains 100 µL of human recombinant SIRT1. Thaw the enzyme on ice, add 300 µL of diluted Assay Buffer to the vial, and vortex. The diluted enzyme is stable for four hours on ice. One vial of enzyme is enough SIRT1 to assay 80 wells. Use the additional vial if assaying the entire plate.
- ✓ SIRT1 Direct Peptide - Each vial contains 100 µL of a 5 mM peptide solution comprising amino acids 379-382 of human p53 conjugated to aminomethylcoumarin (AMC). It is ready to use to make the substrate solution.
- ✓ SIRT1 Direct NAD⁺ - The vial contains 500 µL of a 50 mM solution of NAD⁺. It is ready to use to make the substrate solution.
- ✓ SIRT1 Direct Nicotinamide - The vial contains 500 µL of a 50 mM solution of nicotinamide, a sirtuin inhibitor. It is ready to use to make the Stop/Developing Solution.
- ✓ SIRT1 Direct Developer - The vial contains the SIRT1 developer.
- ✓ SIRT1 Direct Fluorophore - The vial contains 50 µL of 10 mM 7-amino-4-methylcoumarin in DMSO. The fluorophore can be used to assay for interference.
- ✓ Plate Set Up - There is no specific pattern for using the wells on the plate. However, it is necessary to have three wells designated as 100% initial activity and three wells designated as background wells. We suggest that each inhibitor/activator sample be assayed in triplicate and that you record the contents of each well on the template sheet provided on Plate Layout. A typical layout of samples and compounds to be measured in triplicate is given in Plate Layout.

Assay Procedure

1. Preparation of Substrate solution - To one of the thawed SIRT1 peptide vials, add 240 µL of NAD⁺ solution, and 850 µL of diluted Assay Buffer. One vial of peptide will make enough substrate solution for 79 wells. The substrate solution is stable for six hours. The addition of 15 µL to the assay yields a final concentration of 125 µM peptide and 3 mM NAD⁺.
Note: The K_m values for the peptide and NAD⁺ are 200 and 435 µM, respectively.
2. 100% Initial Activity Wells - add 25 µL of Assay Buffer, 5 µL of diluted SIRT1, and 5 µL of solvent (the same solvent used to dissolve the inhibitor/activator) to three wells.
3. Background Wells - add 30 µL of Assay Buffer and 5 µL of solvent (the same solvent used to dissolve the inhibitor/activator) to three wells.

4. Inhibitor/Activator* Wells - add 25 μ L of Assay Buffer, 5 μ L of diluted SIRT1, and 5 μ L of inhibitor/activator* to three wells.
5. Initiate the reactions by adding 15 μ L of substrate solution to all the wells being used.
6. Cover the plate with the plate cover and incubate on a shaker for 45 minutes at room temperature.
7. Preparation of Stop/Developing solution - Weigh 30 mg of Developer into a vial that will hold 5 mL then add 200 μ L of Nicotinamide and 4.8 mL of diluted Assay Buffer. Vortex until the Developer is into solution. This is enough Stop/Developing solution for the entire plate. The Stop/ Developing solution is stable for four hours on ice.
8. Remove the plate cover and add 50 μ L of Stop/Developing solution to each well. Cover the plate with the plate cover and incubate for 30 minutes at room temperature.
9. Remove the plate cover and read the plate in a fluorometer using an excitation wavelength of 350-360 nm and an emission wavelength of 450-465 nm. It may be necessary to adjust the gain setting on the instrument to allow for the measurement of all the samples. The fluorescence is stable for 30 minutes.

*The compounds should be dissolved in Assay Buffer whenever possible. Alternatively, compounds may be prepared in DMSO as long as the final concentration in the assay is $<2\%$. If another organic solvent is used, experiments must be performed to test for solvent effects.

✓ General Information

- The final volume of the assay is 100 μ L in all the wells.
- Use the diluted Assay Buffer in the assay.
- All reagents except SIRT1 and Stop/Developing Solution must be equilibrated to room temperature before beginning the assay.
- It is not necessary to use all the wells on the plate at one time.
- If the appropriate inhibitor/activator dilution is not known, it may be necessary to assay at several dilution.
- We recommend assaying samples in triplicate, but it is the user's discretion to do so.
- Thirty inhibitor/activator samples can be assayed in triplicate or forty-six in duplicate.
- The assay is performed at 22-25°C.
- Monitor the fluorescence on a fluorometer with an excitation wavelength of 350-360 nm and an emission wavelength of 450-465 nm.

Data Analysis

Calculation of Results

1. Determine the average fluorescence of each sample.
2. Subtract the fluorescence of the background wells from the fluorescence of the 100% initial activity and the inhibitor/activator wells.
3. Determine the percent inhibition/activation for each sample. To do this, subtract each inhibitor/activator sample value from the 100% initial activity sample value. Divide the result by the 100% initial activity value and then multiply by 100 to give the percent inhibition/activation.
4. Either graph the Percent Inhibition or Percent Initial Activity as a function of the inhibitor concentration to determine the IC₅₀ value (concentration at which there was 50% inhibition). An example of SIRT1 inhibition by Sirtinol, a sirtuin-specific inhibitor is shown in Figure 2.^{19,20}

$$\% \text{ Inhibition/Activation} = \left[\frac{\text{Initial Activity} - \text{Sample}}{\text{Initial Activity}} \right] \times 100$$




Figure 2. Inhibition of SIRT1 by Sirtinol (IC₅₀ = 38 µM)

Performance Characteristics

✓ Precision

When a series of sixteen SIRT1 measurements were performed on the same day, the intra-assay coefficient of variation was 2.5%. When a series of sixteen SIRT1 measurements were performed on five different days under the same experimental conditions, the inter-assay coefficient of variation was 4.3%.

✓ Interferences

It is possible that a compound tested for SIRT1 inhibition/activation will interfere with the development of the assay or interfere with the fluorophore. Potential fluorophore interference can be tested by assaying

the compound in question with the fluorophore. A procedure is outlined below.

✓ Testing for Fluorophore Interference

1. Dilute 20 μL of fluorophore with 480 μL of diluted assay buffer.
2. Fluorophore wells - add 5 μL of diluted fluorophore, 5 μL of solvent (the same solvent used to dissolve the compound), and 90 μL of diluted assay buffer to three wells.
3. Compound wells - add 5 μL of diluted fluorophore, 5 μL of compound, and 90 μL of diluted assay buffer to three wells.
4. Cover the plate with the plate cover and incubate for 10 minutes at room temperature.
5. Remove the plate cover and read the plate in a fluorometer using an excitation wavelength of 350-360 nm and an emission wavelength of 450-465 nm. It may be necessary to adjust the gain setting on the instrument to allow for the measurement of all the samples.

✓ Calculating the Percent Fluorophore Interference

1. Determine the average fluorescence of each sample.
2. Determine the percent interference for the compound. To do this, subtract each compound value from the fluorophore value. Divide the result by the fluorophore value and then multiply by 100 to give the percent interference. The percent interference should be less than 10% for the compound to be not affecting the fluorophore.

✓ Testing for Developer Interference

1. SIRT1 wells - add 25 μL of assay buffer and 5 μL of diluted SIRT1 to three wells.
2. Compound wells - add 25 μL of assay buffer and 5 μL of diluted SIRT1 to three wells.
3. Initiate the reactions by adding 15 μL of substrate solution to all the wells being used.
4. Cover the plate with the plate cover and incubate on a shaker for 45 minutes at room temperature.
5. Remove the plate cover and add 50 μL of Stop/Developing solution to the SIRT1 and Compound wells.
6. Add 5 μL of compound to the Compound wells and 5 μL of solvent (the same solvent used to dissolve the compound) to the SIRT1 wells.
7. Cover the plate with the plate cover and incubate for 30 minutes at room temperature.
8. Remove the plate cover and read the plate in a fluorometer using an excitation wavelength of 350-360 nm and an emission wavelength of 450-465 nm. It may be necessary to adjust the gain setting on the instrument to allow for the measurement of all the samples.

✓ Calculating the Percent Developer Interference

1. Determine the average fluorescence of each sample.
2. Determine the percent interference for the compound. To do this, subtract each compound value from the SIRT1 value. Divide the result by the SIRT1 value and then multiply by 100 to give the percent interference. The percent interference should be less than 10% for the compound to be not affecting the developer.

Resources

Troubleshooting

Problem	Possible Causes	Recommended Solutions
Erratic values; dispersion of duplicates/triplicates	A. Poor pipetting/technique B. Bubble in the well(s)	A. Be careful not to splash the contents of the wells B. Carefully tap the side of the plate with your finger to remove bubbles
No fluorescence detected above background in any of the wells	Either SIRT1 or Developer was not added to the wells	Make sure to add all the components to the wells and re-assay
The fluorometer exhibited "MAX" values for the wells	The GAIN setting is too high	Reduce the GAIN and re-read
No inhibition/activation seen with compound	A. The compound concentration is not high enough B. The compound is not an inhibitor/activator of the enzyme	Increase the compound concentration and re-assay

References

1. Grunstein, M. Histone acetylation in chromatin structure and transcription. *Nature* 389, 349-352 (1997).
2. Strahl, B.D. and Allis, D. The language of covalent histone modifications. *Nature* 403, 41-45 (2000).
3. Cheung, W.L., Briggs, D.B., and Allis, C.D. Acetylation and chromosomal functions. *Curr. Opin. Cell Biol.* 12, 326-333 (2000).
4. Imai, S.-I., Armstrong, C.M., Kaeberlein, M., *et al.* Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. *Nature* 403, 795-800 (2000).
5. Tanner, K.G., Landry, J., Sternglanz, R., *et al.* Silent information regulator 2 family of NAD-dependent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose. *Proc. Natl. Acad. Sci. USA* 97(26), 14178-14182 (2000).
6. Tanny, J. C., Moazed, D. Coupling of histone deacetylation to NAD breakdown by the yeast silencing protein Sir2: Evidence for acetyl transfer from substrate to an NAD breakdown product. *Proc. Natl. Acad. Sci. USA* 98(2), 415-420 (2001).
7. Frye, R.A. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. *Biochem. Biophys. Res. Commun.* 273, 793-798 (2000).

8. Luo, J., Nikolaev, A.Y., Imai, S.-I., *et al.* Negative control of p53 by Sir2 promotes cell survival under stress. *Cell* 107, 137-148 (2001).
9. Vaziri, H., Dessain, S.K., Eaton, E.N., *et al.* hSIR2^{SIRT1} functions as an NAD-dependent p53 deacetylase. *Cell* 107, 149-159 (2001).
10. Langley, E., Pearson, M., Faretta, M., *et al.* Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. *EMBO J.* 21(10), 2383-2396 (2002).
11. Longo, V.D. and Kennedy, B.K. Sirtuins in aging and age-related disease. *Cell* 126, 257-268 (2006).
12. Saunders, L.R., Verdin, E. Sirtuins: critical regulators at the crossroads between cancer and aging. *Oncogene* 26, 5489-5504 (2007).
13. Howitz, K.T., Bitterman, K.J., Cohen, H.Y., *et al.* Small molecule activators of sirtuins extend *Saccharomyces cerevisiae* lifespan. *Nature* 425, 191-196 (2003).
14. Wood, J.G., Rogina, B., Lavu, S., *et al.* Sirtuin activators mimic caloric restriction and delay ageing in metazoans. *Nature* 430, 686-689 (2004).
15. Borra, M.T., Smith, B.C., and Denu, J.M. Mechanism of human SIRT1 activation by resveratrol. *J. Biol. Chem.* 280(17), 17187-17195 (2005).
16. Kaeberlein, M., McDonagh, T., Heltweg, B., *et al.* Substrate-specific activation of sirtuins by resveratrol. *J. Biol. Chem.* 280(17), 17038-17045 (2005).
17. Yamamoto, H., Schoonjans, K., Auwerx, J. Sirtuin functions in health and disease. *Mol. Endocrinol.* 21(8), 1745-1755 (2007).
18. Westphal, C.H., Dipp, M.A., Guarente, L. A therapeutic role for sirtuins in diseases of aging? *Trends Biochem. Sci.* 32(12), 555-560 (2007).
19. Grozinger, C.M., Chao, E.D., Blackwell, H.E., *et al.* Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. *J. Biol. Chem.* 276(42), 38837-38843 (2001).
20. Denu, J.M. The Sir2 family of protein deacetylases. *Current Opinion in Chemical Biology* 9, 431-440 (2005).

Plate Layout

	1	2	3	4	5	6	7	8	9	10	11	12
A	Background Wells	Background Wells	Background Wells	Sample 7	Sample 7	Sample 7	Sample 15	Sample 15	Sample 15	Sample 23	Sample 23	Sample 23
B	100% Initial Activity Wells	100% Initial Activity Wells	100% Initial Activity Wells	Sample 8	Sample 8	Sample 8	Sample 16	Sample 16	Sample 16	Sample 24	Sample 24	Sample 24
C	Sample 1	Sample 1	Sample 1	Sample 9	Sample 9	Sample 9	Sample 17	Sample 17	Sample 17	Sample 25	Sample 25	Sample 25
D	Sample 2	Sample 2	Sample 2	Sample 10	Sample 10	Sample 10	Sample 18	Sample 18	Sample 18	Sample 26	Sample 26	Sample 26
E	Sample 3	Sample 3	Sample 3	Sample 11	Sample 11	Sample 11	Sample 19	Sample 19	Sample 19	Sample 27	Sample 27	Sample 27
F	Sample 4	Sample 4	Sample 4	Sample 12	Sample 12	Sample 12	Sample 20	Sample 20	Sample 20	Sample 28	Sample 28	Sample 28
G	Sample 5	Sample 5	Sample 5	Sample 13	Sample 13	Sample 13	Sample 21	Sample 21	Sample 21	Sample 29	Sample 29	Sample 29
H	Sample 6	Sample 6	Sample 6	Sample 14	Sample 14	Sample 14	Sample 22	Sample 22	Sample 22	Sample 30	Sample 30	Sample 30